Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, Kate de Santis, Director, Inv
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a lower net loss allocable to common stockholders in ... share, compared to a net loss allocable to common stockholders in ... share, and a net loss allocable to common stockholders in the ...
... TessArae® LLC, a global leader in resequencing microarray-based ... solutions for genetic testing of the mutations that ... TessArae,s expertise in microarray-based resequencing with novel nucleotide ... for all targeted mutations in multiple genes of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2
(Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
(Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
(Date:4/24/2014)... prescription opioid overdose deaths was outlined yesterday in the ... of agencies in the U.S. Department of Health and ... providers to expand their use of medications to treat ... number of misperceptions that have limited access to these ... can be used in combination with behavior therapies to ...
(Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU Health ... Undergraduates (REU) Site grant in the amount of ... undergraduates from diverse social and educational backgrounds, underrepresented ... area. The project will provide students with ... 2014-16. It will be led by Principal ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
... a healthy diet appears to lower blood pressure in ... in women with high blood pressure, according to a ... ,The American Heart Association estimates that high ... 1 billion individuals worldwide. The most common-and deadly-result is ...
... here allegedly committed suicide Tuesday morning , with police attributing ... of the orthopaedics department, was found dead at around 7.00 ... south Delhi. ,Sharma, who is said to have ... around 6.00 a.m. to monitor his patients. After 20 minutes ...
... a super sleuth of potentially deadly prescription drug reactions. ... RADAR (Research on Adverse Drug Events and Reports) ... swoop in to investigate early signs of trouble years ... ,A new study by Bennett, the A.C. ...
... recently examined how researchers in Tanzania are training rats ... researchers' efforts "capitalize" on the rats' strong sense of ... ,Bart Weetjens, a former industrial designer, developed the idea ... land mines, after he visited minefields and saw German ...
... may be the disease generally identified with the third ... its tentacles everywhere. US authorities fear that an American ... flights this month to the potentially lethal disease. The ... authorities are looking for travelers who were aboard Air ...
... accumulating that depression is a risk factor for osteoporosis, ... Watch. A recent study found that people ages ... serotonin reuptake inhibitors (SSRIs) had double the rate of ... points to depression itself as a source of endocrine ...
Cached Medicine News:Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 3Health News:Researchers Training Rats To Diagnose TB 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 3
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
... Anti-HTLV Mixed Titer Performance Panel consists of ... to strong positive for antibodies to HTLV ... for use by manufacturers and diagnostic laboratories ... data from all major test systems are ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
Medicine Products: